文献速递临床试验与 GCP基础与转化研究

单体和寡聚体黄烷醇用于2型糖尿病合并微量白蛋白尿患者饮食管理(FLAVA试验):随机对照试验研究方案

Use of monomeric and oligomeric flavanols in the dietary management of patients with type 2 diabetes mellitus and microalbuminuria (FLAVA trial): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-07-16

FLAVA试验是一项双盲、安慰剂对照、随机、多中心研究方案,计划招募96例40-85岁2型糖尿病合并微量白蛋白尿患者,随机接受每日200 mg葡萄籽来源单体和寡聚体黄烷醇(MOF)或安慰剂3个月,主要终点为白蛋白排泄率(AER)随时间变化,次要终点包括ADMA、sVCAM-1、sICAM-1、IL-6和vWF等肾脏内皮功能血浆标志物。

要点

  • 每日200 mg MOF补充3个月,评估对2型糖尿病合并微量白蛋白尿患者AER的影响。
  • 双盲、安慰剂对照、随机、多中心设计,计划招募96例40-85岁患者。
  • 次要终点为ADMA、sVCAM-1、sICAM-1、IL-6和vWF等内皮功能标志物。

核心结论

  • 研究假设2型糖尿病合并微量白蛋白尿患者存在MOF的医学需求,满足该需求可降低AER及相关内皮生物标志物。

研究设计与样本

  • 双盲、安慰剂对照、随机、多中心试验,计划招募96例40-85岁2型糖尿病合并微量白蛋白尿患者。
  • 参与者随机分配至每日200 mg MOF干预组或安慰剂对照组,干预3个月。
  • 采用混合模型进行数据统计分析。

关键数值与推荐

  • 主要终点为干预3个月内白蛋白排泄率(AER)随时间变化,与安慰剂比较。
  • 次要终点为干预3个月内ADMA、sVCAM-1、sICAM-1、IL-6和vWF等血浆标志物随时间变化,与安慰剂比较。
  • 干预剂量为每日200 mg MOF,持续3个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with type 2 diabetes mellitus (T2D) are prone to micro- and macro-vascular complications. Monomeric and oligomeric flavanols (MOF) isolated from grape seeds (Vitis vinifera) have been linked to improved endothelial function and vascular health. The aim of this study is to determine the effect of a daily supplementation of 200 mg MOF on renal endothelial function of patients with T2D and microalbuminuria. METHODS/DESIGN: For this double-blind, placebo-controlled, randomized, multicenter trial 96 individuals (ages 40-85 years) with T2D and microalbuminuria will be recruited. Participants will be randomly assigned to the intervention group, receiving 200 mg of MOF daily for 3 months, or to the control group, receiving a placebo. The primary endpoint is the evolution over time in albumin excretion rate (AER) until 3 months of intervention as compared with placebo. Secondary endpoints are the evolution over time in established plasma markers of renal endothelial function-asymmetric dimethylarginine (ADMA), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular cell adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6), and von Willebrand Factor (vWF)-until 3 months of intervention as compared with placebo. Mixed modeling will be applied for the statistical analysis of the data. DISCUSSION: We hypothesize that T2D patients with microalbuminuria have a medically determined requirement for MOF and that fulfilling this requirement will result in a decrease in AER and related endothelial biomarkers. If confirmed, this may lead to new insights in the dietary management of patients with T2D. TRIAL REGISTRATION: Nederlands Trial Register, NTR4669 , registered on 7 July 2014.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Rashid M, Verhoeven AJM, Mulder MT, et al. Use of monomeric and oligomeric flavanols in the dietary management of patients with type 2 diabetes mellitus and microalbuminuria (FLAVA trial): study protocol for a randomized controlled trial. Trials. 2018. PMID: 30012185. doi:10.1186/s13063-018-2762-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。